Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance
Guidance tracker
What GLAND guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 12 Nov 2026 | Gland Pharma filed the transcript of its Q2 FY27 earnings call held on November 06, 2026. Management reported Q2 FY27 revenue of INR 18,336 million (up 23% YoY), reported EBITDA of INR 4,804 million, adjusted EBITDA of INR 5,030 million (27% margin) and profit after tax of INR 2,908 million (up 58% YoY). Management... NSE copy | No results filed since | ||
| 17 Aug 2026 | Gland Pharma filed the transcript of its Q1FY27 earnings conference call held on August 10, 2026, covering the quarter ended June 30, 2026. Management (Executive Chairman Srinivas Sadu) reported revenue of INR18,003 million, up 20% year-on-year, adjusted EBITDA of INR5,102 million (28% margin) and profit after tax... NSE copy | +58.3 % | +23.3 % | +4.2 % |
| 20 May 2026 | Gland Pharma filed the transcript of its Q4 FY26 earnings conference call, held on May 15, 2026. Management reported Q4 FY26 revenue of INR17,428 million (up 22% year-on-year), adjusted EBITDA of INR5,244 million (30% margin) and adjusted PAT of INR3,667 million (21% margin). For full year FY26, management reported... NSE copy | +47.1 % | +19.6 % | +9.6 % |
| 03 Feb 2026 | Gland Pharma filed the transcript of its Q3 FY26 earnings conference call, held January 28, 2026. Management said Q3 FY26 revenue grew 22% year-on-year to INR 16,954 million and adjusted EBITDA rose 25% to INR 4,490 million, with adjusted EBITDA margin of 26%. For the 9 months ended FY26, consolidated revenue was... NSE copy | +96.6 % | +22.3 % | +15.4 % |
| 07 Nov 2025 | Gland Pharma filed the transcript of its Q2 FY26 earnings conference call, held on November 3, 2025. Management said Q2 FY26 consolidated revenue was INR 14,869 million (up 6% YoY) and consolidated EBITDA was INR 3,139 million (21% margin); H1 FY26 revenue was INR 29,925 million (up 7%) with EBITDA of INR 6,817... NSE copy | +27.7 % | +22.5 % | +6.5 % |
| 27 May 2025 | Gland Pharma filed the transcript of its Q4 FY25 earnings conference call, held on May 20, 2025. Management reported Q4 FY25 consolidated revenue of INR 14,249 million and consolidated EBITDA of INR 3,475 million (24% margin); base business (excluding Cenexi) revenue fell 12% year-over-year to INR 10,332 million.... NSE copy | +49.9 % | +7.4 % | -0.4 % |
| 10 Feb 2025 | Gland Pharma filed the transcript of its Q3 FY25 earnings conference call, held on February 3, 2025. Management said consolidated Q3 FY25 revenue was INR13,841 million with consolidated EBITDA of INR3,600 million (26% margin, up 100 bps year-on-year). Management said base business revenue (excluding Cenexi) was... NSE copy | -3.1 % | -7.3 % | +4.9 % |
| 03 Feb 2025 | Gland Pharma filed its investor presentation on Q3 and 9M FY25 financial results. Consolidated Q3 FY25 revenue from operations was ₹13,841 Mn (down 10% YoY), PAT was ₹2,047 Mn (up 7% YoY) and EBITDA was ₹3,600 Mn (26% margin); 9M FY25 revenue was ₹41,916 Mn (up 2% YoY) and PAT was ₹5,120 Mn (down 12% YoY). Base... NSE copy | -3.1 % | -7.3 % | +4.9 % |
Filings tagged as guidance, newest first (8 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 12 Nov 2026 | Management change | Gland Pharma filed the transcript of its Q2 FY27 earnings call held on November 06, 2026. Management reported Q2 FY27 revenue of INR 18,336 million (up 23% YoY), reported EBITDA of INR 4,804 million, adjusted EBITDA of INR 5,030 million (27% margin) and profit after tax of INR 2,908 million (up 58% YoY). Management... NSE copy |
| 01 Oct 2026 | Management change | Gland Pharma Limited's board approved on October 01, 2026 an investment of USD 21 million by the company in Gland Pharma USA Inc. (Gland USA), to be used to subscribe to 60% of the equity of Novelstar Pharma Inc., a newly incorporated US company, to facilitate expansion in the United States. Gland USA's share... NSE copy |
| 15 Jun 2026 | Management change | Board of Gland Pharma Limited approved re-appointment of Mr. Udo Jahannes Vetter as Independent Director for a second five-year term from July 21, 2026 to July 20, 2031, subject to member approval by postal ballot. Board appointed Mr. William Robert Keller as Additional Director (Non-Executive - Independent) with... NSE copy |
| 09 Apr 2026 | Management change | Gland Pharma Limited's board, at its meeting on April 09, 2026, approved the re-appointment of Ms. Naina Lal Kidwai (DIN: 00017806) as an Independent Director for a second term of five consecutive years. The re-appointment is effective from May 17, 2026 till May 16, 2031. Approval of the members under Regulation... NSE copy |
| 28 Jan 2026 | Management change | Gland Pharma Limited filed the outcome of its board meeting held on January 28, 2026. The board approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, with limited review reports, plus a press release and investor presentation on the results. The... NSE copy |
| 10 Feb 2025 | Legal or regulatory, Management change | Gland Pharma filed the transcript of its Q3 FY25 earnings conference call, held on February 3, 2025. Management said consolidated Q3 FY25 revenue was INR13,841 million with consolidated EBITDA of INR3,600 million (26% margin, up 100 bps year-on-year). Management said base business revenue (excluding Cenexi) was... NSE copy |
| 03 Feb 2025 | Legal or regulatory | Gland Pharma filed its investor presentation on Q3 and 9M FY25 financial results. Consolidated Q3 FY25 revenue from operations was ₹13,841 Mn (down 10% YoY), PAT was ₹2,047 Mn (up 7% YoY) and EBITDA was ₹3,600 Mn (26% margin); 9M FY25 revenue was ₹41,916 Mn (up 2% YoY) and PAT was ₹5,120 Mn (down 12% YoY). Base... NSE copy |
| 03 Feb 2025 | Management change | Gland Pharma's board on February 3, 2025 approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, with limited review reports, a press release and an investor presentation. The board appointed Grant Thornton Bharat LLP as internal auditors for... NSE copy |
| 03 Feb 2025 | Management change | Gland Pharma's board met on February 3, 2025 and approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, with a limited review report from Deloitte Haskins & Sells. The company enclosed a press release and investor presentation on the results, but... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (9 in all). A list of what was filed, not a judgement of the company.